Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bortezomib + cytarabine + dexamethasone in relapsed or refractory mantle cell lymphoma
KCT0004010Phase 2Recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, cytarabine, dexamethasone in mantle cell lymphoma (MCL), sponsored by JW Pharmaceutical Corporation. Started Oct 2016; status: recruiting.
02
Drugs
bortezomibcytarabinedexamethasone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on KCT0004010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004010.